investors.cyteir.comCyteir Therapeutics - Investor
investors.cyteir.com Profile
Investors.cyteir.com is a subdomain of cyteir.com, which was created on 2012-05-30,making it 12 years ago.
Discover investors.cyteir.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investors.cyteir.com Information
| HomePage size: 80.715 KB |
| Page Load Time: 0.251781 Seconds |
| Website IP Address: 162.159.130.11 |
investors.cyteir.com Similar Website
| Aratana Therapeutics Investor Overview |
| Synopsys, Inc. | Investor Relations & Investor Resources |
| Masonite International Corp. - Investor Relations - Investor Relations |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| Investor Relations :: Checkpoint Therapeutics, Inc. (CKPT) |
| Investor Relations | TG Therapeutics, Inc. |
| Revance Therapeutics, Inc. - Investor Relations |
| Investor Overview | Mateon Therapeutics |
| Coya Therapeutics - Investor Relations |
| Investor Relations :: BioXcel Therapeutics, Inc. (BTAI) |
| United Therapeutics Investor Relations |
| Mirati Therapeutics Inc. - Investor & Media Relations |
| Edgewise Therapeutics, Inc. - Investor |
| Halozyme Therapeutics, Inc. - Investor |
investors.cyteir.com PopUrls
| Cyteir Therapeutics - Investor Relations https://investors.cyteir.com/overview/default.aspx |
| Privacy Policy https://investors.cyteir.com/privacy-policy/default.aspx |
| Cookies Policy https://investors.cyteir.com/cookies-policy/default.aspx |
| Terms of Use https://investors.cyteir.com/terms-of-use/default.aspx |
| Cyteir Therapeutics - Investor & Media - News https://investors.cyteir.com/investor-relations/news/default.aspx |
| Investor & Media - Stock Info https://investors.cyteir.com/investor-relations/stock-info/default.aspx |
| Investor & Media - Governance - Committee Composition https://investors.cyteir.com/investor-relations/governance/committee-composition/default.aspx |
| Investor & Media - Financials - SEC Filings https://investors.cyteir.com/investor-relations/financials/sec-filings/default.aspx |
| Investor & Media - Financials - Annual Meeting https://investors.cyteir.com/investor-relations/financials/Annual-Meeting/default.aspx |
| Cyteir Therapeutics Names Adam Veness General Counsel https://investors.cyteir.com/investor-relations/news/news-details/2022/Cyteir-Therapeutics-Names-Adam-Veness-General-Counsel/default.aspx |
investors.cyteir.com Httpheader
| Date: Thu, 16 May 2024 07:39:46 GMT |
| Content-Type: text/html; charset=utf-8 |
| Transfer-Encoding: chunked |
| Connection: keep-alive |
| CF-Ray: 8849b73fafce7afd-SJC |
| CF-Cache-Status: REVALIDATED |
| Cache-Control: public, max-age=10, stale-if-error=86400, stale-while-revalidate=86400 |
| Strict-Transport-Security: max-age=31536000; includeSubDomains |
| Vary: Accept-Encoding |
| X-Content-Type-Options: nosniff |
| X-Frame-Options: SAMEORIGIN |
| X-XSS-Protection: 1; mode=block |
| Server: |
investors.cyteir.com Meta Info
| content="text/html; charset=utf-8" http-equiv="Content-type"/ |
| content="RevealTrans(Duration=0,Transition=0)" http-equiv="Page-Enter"/ |
| content="IE=edge,chrome=1" http-equiv="X-UA-Compatible"/ |
| content="width=device-width, initial-scale=1" name="viewport"/ |
| content="default-src 'self' https: http: 'unsafe-inline' 'unsafe-eval' *.q4inc.com; script-src 'self' *.cloudfront.net *.pusherapp.com *.newrelic.com *.nr-data.net *.bugherd.com *.q4cdn.com *.q4web.com *.amazonaws.com *.highcharts.com *.googletagmanager.com *.googleadservices.com *.google-analytics.com *.google.com *.gstatic.com *.q4app.com *.pendo.io 'unsafe-inline' 'unsafe-eval' *.q4inc.com" http-equiv="Content-Security-Policy"/ |
| content="N01M6uJhe5UWSVEGroFhC-dX7fulsUiQ96E6YYk7VP4" |
investors.cyteir.com Html To Plain Text
Relations Overview Company Pipeline Patients Publications Investor & Media Overview News Events & Presentations Stock Info Stock Quote Financials SEC Filings Annual Meeting Governance Governance Documents Committee Composition Resources Information Request Form Investor Email Alerts Investor Contacts Investor Relations Menu Investor Relations Corporate Overview Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug currently in a Phase 1/2 clinical trial for hematologic and solid tumors.Cyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine and gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer. Read more Latest News View all news Latest Presentation Latest Events View All Events Contact Us [email protected] 99 Hayden Avenue, Building B, Suite 450 Lexington, MA 02421 Quick Links SEC Filings Information Request Form Investor Email Alerts To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. At Cyteir Therapeutics, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance. By providing your email address below, you are providing consent to Cyteir Therapeutics to send you the requested Investor Email Alert updates. * Required Email Address * Investor Alert Options * News Events & Presentations Quarterly Reports Annual Reports SEC Filings End of Day Stock Quote Unsubscribe Email Alert Sign Up Confirmation follow us on facebook follow us on twitter follow us on linkedin Contact Information 99 Hayden Street Building B, Suite 450 Lexington, MA 02421 857.285.4140 Company Scientific ApproachPipeline Patients CareersPublications Investors & Media Contact Terms of Use Privacy Policy Cookies Policy Terms of Use © Q4 Inc. - All rights reserved Powered By Q4 Inc. 5.122.0.3 (opens in...
investors.cyteir.com Whois
Domain Name: CYTEIR.COM Registry Domain ID: 1723990224_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.ionos.com Registrar URL: http://www.ionos.com Updated Date: 2023-05-31T07:45:20Z Creation Date: 2012-05-30T21:00:10Z Registry Expiry Date: 2024-05-30T21:00:10Z Registrar: IONOS SE Registrar IANA ID: 83 Registrar Abuse Contact Email: abuse@ionos.com Registrar Abuse Contact Phone: +1.6105601459 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS1043.UI-DNS.BIZ Name Server: NS1043.UI-DNS.COM Name Server: NS1043.UI-DNS.DE Name Server: NS1043.UI-DNS.ORG DNSSEC: unsigned >>> Last update of whois database: 2024-05-18T04:50:19Z <<<